You may not remember his name, but you will certainly recall Martin Shkreli's story.
He is the 32-year-old drug company entrepreneur who created a media frenzy several months back after he hiked prices of life-saving drug, Daraprim, from $13.50 to $750.
Now, Shkreli finds himself back in the headlines after federal agents arrested him on securities fraud related to a firm he founded.
According to Bloomberg Business, "prosecutors in Brooklyn charged him with illegally taking stock from Retrophin Inc., a biotechnology firm he started in 2011, and using it to pay off debts from unrelated business dealings."
These charges are unrelated to the pharmaceutical drug cost controversy.
